Charles A. Leath III, MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses agents under investigation in cervical cancer.
Charles A. Leath III MD
Advertisement
Articles by Charles A. Leath III MD
Charles A. Leath III MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses results of the phase III GOG 240 trial in advanced cervical cancer.
Charles A. Leath, III, MD, gynecologic oncologist, The University of Alabama at Birmingham, discusses challenges with bevacizumab in the treatment of patients with cervical cancer.
Charles A. Leath III, MD, gyn oncologist at the University of Alabama at Birmingham, discusses the glaring unmet need in cervical cancer.
Advertisement
Latest Updated Articles
Dr. Leath on Agents Under Investigation in Cervical CancerNovember 14th 2019
Dr. Leath Discusses Unmet Need in Cervical CancerJanuary 20th 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
2
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
3
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
4
Dr Morgans on the Design of the ARACOG Trial in Prostate Cancer
5